Skip to main content
. 2014 Nov 26;3(11):e149. doi: 10.1038/psp.2014.47

Figure 2.

Figure 2

Calibration of the model to match the total anti-PCSK9, total PCSK9, and LDLc reduction data from the phase I clinical study for RG7652 (results shown for three dose groups: 150, 300, and 800 mg); blue: individual clinical subjects; red: mean and 10–90 percentile range for virtual subjects. LDLc, low density lipoprotein cholesterol.